Geode Capital Management LLC Has $9.42 Million Stock Position in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)

Geode Capital Management LLC grew its position in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) by 0.6% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 554,984 shares of the biotechnology company’s stock after purchasing an additional 3,186 shares during the period. Geode Capital Management LLC owned about 2.05% of Arcturus Therapeutics worth $9,421,000 at the end of the most recent quarter.

Other institutional investors have also made changes to their positions in the company. Franklin Resources Inc. raised its position in Arcturus Therapeutics by 54.6% during the third quarter. Franklin Resources Inc. now owns 103,936 shares of the biotechnology company’s stock valued at $2,412,000 after acquiring an additional 36,714 shares in the last quarter. Empire Life Investments Inc. increased its position in Arcturus Therapeutics by 85.5% during the fourth quarter. Empire Life Investments Inc. now owns 279,463 shares of the biotechnology company’s stock worth $4,742,000 after buying an additional 128,771 shares during the last quarter. Hennion & Walsh Asset Management Inc. raised its holdings in Arcturus Therapeutics by 139.7% during the fourth quarter. Hennion & Walsh Asset Management Inc. now owns 82,057 shares of the biotechnology company’s stock valued at $1,393,000 after buying an additional 47,824 shares in the last quarter. Spire Wealth Management lifted its position in shares of Arcturus Therapeutics by 393.3% in the fourth quarter. Spire Wealth Management now owns 13,478 shares of the biotechnology company’s stock worth $229,000 after buying an additional 10,746 shares during the last quarter. Finally, SG Americas Securities LLC boosted its stake in shares of Arcturus Therapeutics by 45.0% during the 4th quarter. SG Americas Securities LLC now owns 11,940 shares of the biotechnology company’s stock worth $203,000 after acquiring an additional 3,705 shares in the last quarter. 94.54% of the stock is currently owned by institutional investors and hedge funds.

Arcturus Therapeutics Price Performance

NASDAQ ARCT opened at $12.65 on Thursday. The company’s fifty day moving average is $12.97 and its two-hundred day moving average is $16.24. Arcturus Therapeutics Holdings Inc. has a 52-week low of $8.04 and a 52-week high of $45.00. The firm has a market capitalization of $343.07 million, a price-to-earnings ratio of -5.70 and a beta of 3.41.

Arcturus Therapeutics (NASDAQ:ARCT) last released its earnings results on Thursday, March 6th. The biotechnology company reported ($1.11) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.78). The firm had revenue of $22.77 million for the quarter, compared to analyst estimates of $44.64 million. Arcturus Therapeutics had a negative return on equity of 22.39% and a negative net margin of 36.39%. As a group, sell-side analysts expect that Arcturus Therapeutics Holdings Inc. will post -2.22 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages recently weighed in on ARCT. Wells Fargo & Company cut their price objective on Arcturus Therapeutics from $58.00 to $50.00 and set an “overweight” rating on the stock in a research note on Friday, March 7th. Cantor Fitzgerald restated an “overweight” rating on shares of Arcturus Therapeutics in a research note on Friday, March 7th. HC Wainwright reiterated a “buy” rating and issued a $60.00 target price on shares of Arcturus Therapeutics in a research note on Thursday, April 10th. BTIG Research set a $48.00 target price on shares of Arcturus Therapeutics and gave the stock a “buy” rating in a research report on Monday, March 10th. Finally, Canaccord Genuity Group lowered their price target on Arcturus Therapeutics from $74.00 to $68.00 and set a “buy” rating on the stock in a research report on Monday, March 10th. Seven equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $59.20.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.